Characterization of a case series of mastocytosis in a care center in Cali, Colombia
Caracterización de una serie de casos de mastocitosis en un centro de atención de Cali, Colombia
Article Sidebar
PDF (Español (España))
FLIP
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Main Article Content
Mastocytosis are a group of diseases characterized by the pathological increase and accumulation of mast cells in one or several organs. They can be divided into variants of cutaneous mastocytosis CM, systemic mastocytosis SM and localized mast cell tumors. They are considered extremely rare diseases, also with limitations in their detection given the current lack of knowledge and the recent consensus of their diagnostic criteria. There is no clarity on therapeutic strategies. In Colombia there are few articles that report isolated cases. Objective: To identify the frequency, risk factors, clinical and paraclinical response to treatment of patients with mastocytosis in a reference center in the city of Cali, between June 2004 and June 2019. Method: A retrospective review was made of cases of mastocytosis that occurred in a period of 15 years in the reference center. Finding 7 patients until the period of June 2019. The diagnosis was made according to the existing WHO guidelines and was confirmed with a skin biopsy for patients with CM, and with a bone marrow biopsy for patients with SM. The serum tryptase level was estimated in all patients. Characterization of variables was carried out. Which were analyzed with Stata 13.0 siftware. Informed consent was obtained from each patient according to the guidelines of the local ethics committee. Results: 4 cases of CM and 3 cases of SM were identified. Conclusion: The findings of this series are comparable to those reported in the world literature.
Downloads
Article Details
Akin C, Valent P. Diagnostic criteria and classification of mastocytosis in 2014. Immunol Allergy Clin North Am [Internet]. 2014;34(2):207–18. Disponible en: http://dx.doi.org/10.1016/j.iac.2014.02.003
Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: State of the art in 2010 and future perspectives. Expert Rev Hematol [Internet]. 2010;3(4):497–516. Disponible en: https://doi.org/10.1586/ehm.10.42
Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, et al. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; The American Academy of Allergy, Asthma & Immunology; And the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol [Internet]. 2016;137(1):35–45. Disponible en: https://doi.org/10.1016/j.jaci.2015.08.034
Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: A consensus proposal. Leuk Res [Internet]. 2001;25(7):603–25. Disponible en: https://doi.org/10.1016/s0145-2126(01)00038-8
Valent P, Akin C, Metcalfe DD. Review Article Mastocytosis : 2016 updated WHO classi fi cation and novel emerging treatment concepts. Blood [Internet]. 2017;129(11):1420–8. Disponible en: https://doi.org/10.1182/blood-2016-09-731893
Hannaford R, Rogers M. Presentation of cutaneous mastocytosis in 173 children. Australas J Dermatol [Internet]. 2001;42(1):15–21. Disponible en: https://doi.org/10.1046/j.1440-0960.2001.00466.x
Cohen SS, Skovbo S, Vestergaard H, Kristensen T, Møller M, Bindslev-Jensen C, et al. Epidemiology of systemic mastocytosis in Denmark. Br J Haematol [Internet]. 2014;166(4):521–8. Disponible en: https://doi.org/10.1111/bjh.12916
Arock M, Sotlar K, Akin C, Broesby-Olsen S, Hoermann G, Escribano L, et al. KIT mutation analysis in mast cell neoplasms: Recommendations of the European Competence Network on Mastocytosis. Leukemia [Internet]. 2015;29(6):1223–32. Disponible en: https://doi.org/10.1038/leu.2015.24
Kluin-Nelemans HC, Reiter A, Illerhaus A, van Anrooij B, Hartmann K, Span LFR, et al. Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. Leukemia [Internet]. 2020;34(4):1090–101.
Horny HP, Sotlar K, Valent P, Hartmann K. Mastocytosis - A disease of the hematopoietic stem cell. Dtsch Arztebl [Internet]. 2008;105(40):686–92. Disponible en: https://doi.org/10.1038/s41375-019-0632-4
Pardanani A, Tefferi A. Systemic mastocytosis in adults: A review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr Opin Hematol [Internet]. 2010;17(2):125–32. Disponible en: https://doi.org/10.1097/MOH.0b013e3283366c59
Solis U, Luis J, González V, Geovanny B, Cajo H. Manifestaciones óseas de la mastocitosis cutánea. Presentación de un caso Rev Colomb Reumatol [Internet]. 2016;23(4):266–70. Disponible en: https://doi.org/10.1016/j.rcreu.2016.06.006
Hernández EM, Olguín PO, Sánchez ÁMR, Gómez AV. Mastocytic lentiginous pigmentation. Med Cutan Ibero Lat Am [Internet]. 2020;48(1):80–4. Disponible en: https://doi.org/10.35366/93983
Suso L, Merino A, Parra V, Innocenti C. Mastocitosis Cutáneas a Propóito De Tres Casos De Urticaria Pigmentosa. Rev MÉDICA Univ - Fac Ciencias Médicas -UNCuyo [Internet]. 2015;11(1):1–6. Disponible en: https://bdigital.uncu.edu.ar/6792.
Dumas L, Peroni D, Maino O, Acuña C, Tubio R. Mastocitosis Cutánea En Niños: Reporte De 23 Casos En 5 Años. Rev Argent Dermatol [Internet]. 2019;100(2):41–50. Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S1851-300X2019000200041&lng=es.
Ávila R JA, Cala D JC, Gelvis R JA, Torres G V, Mosquera S H. Urticaria Pigmentosa in Adults. Med UNAB. 2012;15(1):63–7.
Czarny J, Lange M, Ługowska-Umer H, Nowicki RJ. Cutaneous mastocytosis treatment: Strategies, limitations and perspectives. Postep Dermatol Alergol [Internet]. 2018;35(6):541–5. Disponible en: https://doi.org/10.5114/ada.2018.77605
Vikse J, Omdal R. Fatigue in Mastocytosis: A Case Series. Clin Ther [Internet]. 2019;41(4):625–32. Disponible en: https://doi.org/10.1016/j.clinthera.2019.01.016
Matito A, Álvarez-Twose I, Morgado JM, Sánchez-Muñoz L, Orfao A, Escribano L. Clinical impact of pregnancy in mastocytosis: A study of the Spanish network on mastocytosis (REMA) in 45 cases. Int Arch Allergy Immunol [Internet]. 2011;156(1):104–11. Disponible en: https://doi.org/10.1159/000321954
Hartmann K, Henz BM. Cutaneous mastocytosis. Atlas Genet Cytogenet Oncol Haematol. 2020;24(2):83–6.
Bhullar H, Martyres R, Nicholls K, Varigos G, Douglass J, Saracino A. Mastocytosis: a case series of 107 consecutive patients. Br J Dermatol [Internet]. 2018;178(1):e28–9. Disponible en: https://doi.org/10.1111/bjd.15729
Desmond DH, Carmichael MG. Systemic Mastocytosis: The Difficult Patient with a Rare Disease. Case Presentation and Brief Review. Hawaii J Med Public Health [Internet]. 2018;77(2):27–9. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/29435387%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5801525
Sperr WR, Jordan JH, Fiegl M, Escribano L, Bellas C, Dirnhofer S, et al. Serum tryptase levels in patients with mastocytosis: Correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol. [Internet]. 2002;128(2):136–41. Disponible en: https://doi.org/10.1159/000059404
Lange M, Niedoszytko M, Nedoszytko B, Łata J, Trzeciak M, Biernat W. Diffuse cutaneous mastocytosis: Analysis of 10 cases and a brief review of the literature. J Eur Acad Dermatology Venereol [Internet]. 2012;26(12):1565–71. Disponible en: https://doi.org/10.1111/j.1468-3083.2011.04350.x
Schwartz LB, Irani AMA. Serum tryptase and the laboratory diagnosis of systemic mastocytosis. Hematol Oncol Clin North Am [Internet]. 2000;14(3):641–57. Disponible en: https://doi.org/10.1016/s0889-8588(05)70300-2
Heide R, Van Doorn K, Mulder PG, Van Toorenenbergen AW, Beishuizen A, De Groot H, et al. Serum tryptase and SCORMA (SCORing MAstocytosis) Index as disease severity parameters in childhood and adult cutaneous mastocytosis. Clin Exp Dermatol [Internet]. 2009;34(4):462–8. Disponible en: https://doi.org/10.1111/j.1365-2230.2008.03005.x
Leder K, Weller PF. Eosinophilia and helminthic infections. Bailliere’s Best Pract Res Clin Haematol [Internet]. 2000;13(2):301–17. Disponible en: https://doi.org/10.1053/beha.1999.0074
Pardanani A, Lim KH, Lasho TL, Finke C, McClure RF, Li CY, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood [Internet]. 2009;114(18):3769–72. Disponible en: http://dx.doi.org/10.1182/blood-2009-05-220145
Valent P, Akin C, Sperr WR, Mayerhofer M, Föinger M, Fritsche-Polanz R, et al. Mastocytosis: Pathology, genetics, and current options for therapy. Leuk Lymphoma [Internet]. 2005;46(1):35–48. Disponible en: https://doi.org/10.1080/10428190400010775
Siebenhaar F, Akin C, Bindslev-Jensen C, Maurer M, Broesby-Olsen S. Treatment strategies in mastocytosis. Immunol Allergy Clin North Am [Internet]. 2014;34(2):433–47. Disponible en: https://doi.org/10.1016/j.iac.2014.01.012
Mimiola E, Bomben R, De Matteis G, Perbellini O, Guglielmelli P, Bonifacio M, et al. Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases. Hematol Oncol [Internet]. 2019;37(5):628–33. Disponible en: https://doi.org/10.1002/hon.2680
Hadzijusufovic E, Peter B, Gleixner K V, Schuch K, Pickl WF, Thaiwong T, et al. H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. Exp Hematol [Internet]. 2010;38(10):896–907. Disponible en: http://dx.doi.org/10.1016/j.exphem.2010.05.008
Arock M, Akin C, Hermine O, Valent P. Current treatment options in patients with mastocytosis: Status in 2015 and future perspectives. Eur J Haematol [Internet]. 2015;94(6):474–90. Disponible en: https://doi.org/10.1111/ejh.12544
Alvarez-twose I, Matito A, Morgado JM, Sánchez- L, Jara-acevedo M, García-montero A, et al. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature [Internet]. 2017;8(40):68950–63. Disponible en: www.impactjournals.com/oncotarget/
